Cosmetic Research Analysis

In APP/PS1 mice, 90-day oral polystyrene nanoplastic exposure worsened cognition and hippocampal injury while augmenting collagen–integrin-mediated neuroglial signaling. Pharmacologic integrin blockade (TC‑I 15) attenuated collagen activation and rescued cognition. Human single‑nucleus RNA‑seq corroborated upregulated collagen signaling in AD brains, indicating a translatable, druggable exposure–disease pathway.

Impact: Uncovers a mechanistic, druggable collagen–integrin link between environmental nanoplastic exposure and AD progression, with cross-species validation and therapeutic rescue.

Clinical Implications: Supports public health strategies to limit micro/nanoplastic exposure and motivates exploration of collagen–integrin inhibitors or biomarkers in at-risk AD populations; human translational studies remain necessary.

In a murine Trypanosoma cruzi model, a 3D-printed amorphous nifurtimox formulation improved dissolution/bioavailability, achieved superior parasitemia control versus conventional nifurtimox, modulated tissue inflammatory cytokines, and at 100 mg/kg produced complete parasite clearance with sustained protection even under immunosuppression.

Impact: Demonstrates that a solid-state/manufacturing strategy (3D printing → amorphization) can materially increase efficacy and enable lower-dose use of an existing drug—generalizable to hydrophobic actives in dermatology/cosmeceuticals.

Clinical Implications: Supports advancement to GLP toxicology and early human studies; informs formulation approaches for other hydrophobic actives used in dermatology and cosmetics to reduce dose-related toxicity.

A CRISPR/Cas9 transgenic zebrafish platform expressed human Col3a1 to yield a collagen composite with high thermal stability and intact fibrillar architecture. In vitro assays showed anti-inflammatory modulation and fibroblast proliferation, and murine wound models achieved >95% closure by day 15 with improved neoskin thickness and collagen deposition.

Impact: Demonstrates a scalable production route for functionally intact human type III collagen with in vivo efficacy, bridging biomaterials engineering and therapeutic dermatology.

Clinical Implications: If immunogenicity and GMP manufacturing are addressed, the platform could enable next-generation dressings, scaffolds, or dermal regeneration products for reconstructive and aesthetic indications.

In a multicenter phase II randomized intra-patient controlled trial (n=23), denovoSkin™, an autologous bio-engineered dermo-epidermal graft, achieved significantly better observer-rated scar quality at 3 months compared with paired split-thickness grafts, with feasibility and safety demonstrated over 1 year.

Impact: Provides randomized, intra-patient controlled evidence that a tissue-engineered autologous skin substitute can improve scar outcomes and reduce donor-site morbidity versus standard grafting.

Clinical Implications: DenovoSkin may be considered as an alternative to STSG in full-thickness defects and burn reconstruction pending phase III confirmation, informing reconstructive planning and patient counseling about scar quality and donor-site trade-offs.

Using hESC-derived neural crest melanocyte differentiation and multi-timepoint single-cell RNA-seq, the study identifies CD68 as a previously unrecognized component of the melanogenic regulatory network, co-expressed with MITF, TYR, and TYRP1. Functional knockdown impaired melanin synthesis, proliferation, and MAPK activation, nominating CD68 as a potential target for pigmentary disorders. This mechanistic insight expands the landscape for cosmetic depigmenting strategies.

Impact: First demonstration that CD68 regulates melanocyte development and melanogenesis, creating a mechanistic foothold for next-generation depigmenting approaches.

Clinical Implications: Supports exploration of CD68 modulation for pigmentary disorders (e.g., melasma, vitiligo); next steps include in vivo validation, druggability profiling, and biomarker development.

In a multicenter randomized, evaluator-blinded trial (n=174), PLLA injections produced robust and durable improvement in temple hollowing: 96.5% achieved ≥1-grade ATHS improvement at 6 months versus 0% in controls, with gains across GAIS, 3D volumetry, and satisfaction persisting to 12 months; no therapy-related adverse events were reported.

Impact: Provides rigorous randomized evidence that PLLA is an effective, durable, and well-tolerated option for temporal augmentation—directly informing aesthetic practice.

Clinical Implications: Consider PLLA as a minimally invasive, durable alternative to HA or fat grafting for temple hollowing; counsel on ~12-month durability and the need for head-to-head and longer-term data.

An injectable bioadhesive (CγR) combining carboxymethyl chitosan, γ‑polyglutamic acid, and autologous PRP achieved >99.9% bactericidal activity, rapid wet‑tissue adhesion, sustained growth factor release, and sterile sealing with complete epithelialization by day 6 in infected rat wounds.

Impact: Condenses suture, antibiotic, and dressing functions into a scalable platform integrating antimicrobial and regenerative signaling—promising for contaminated wounds in aesthetic/reconstructive practice.

Clinical Implications: If translated to humans, this one-step bioadhesive could reduce infection rates and accelerate closure in contaminated traumatic or surgical wounds; human toxicology and randomized trials are needed.

A hybrid, time-resolved pharmacodynamic in silico model calibrated to 49 clinical trials simulated dose–response and duration for six BoNT-A products, showing substantial drift in static conversion ratios over time and identifying decay rate (koff) as the dominant determinant of duration. PrabotulinumtoxinA and daxibotulinumtoxinA ranked highest for efficiency and persistence. The work recommends product- and time-specific dosing in aesthetic practice.

Impact: Data-driven modelling challenges fixed unit conversions for BoNT-A by demonstrating time-dependent differences in duration and efficiency, with immediate implications for individualized dosing.

Clinical Implications: Avoid static conversion ratios when switching BoNT-A products; tailor dosing to product-specific, time-resolved equivalence and the desired duration/response.

Hyaluronic acid–butyrate conjugates, especially 5 kDa HAB, enhanced skin retention ~6.5-fold over free butyrate via CD44 targeting and CES2-triggered local release in inflamed skin. In DNFB-induced AD mice, 5k-HAB accelerated lesion resolution, reduced TEWL and erythema, restored hydration and barrier proteins, and mitigated oxidative stress and inflammatory cytokines.

Impact: Validates a disease-responsive dermal delivery platform that prioritizes retention over penetration with mechanistic (CD44/CES2) and in vivo efficacy.

Clinical Implications: Supports development of HA-based topical formulations for AD that enhance local efficacy while reducing systemic exposure; next steps include ex vivo human skin testing and early-phase trials.

Preclinical studies show DHT downregulates FLG2 in dermal papilla cells; hyaluronic acid microneedles delivering recombinant FLG2 restored DPC viability and mitochondrial function, prolonged anagen, and increased follicle density in mouse AGA models.

Impact: Identifies FLG2 as a novel, mechanism-based target for AGA and demonstrates minimally invasive biologic delivery with in vivo efficacy.

Clinical Implications: Pending human safety and immunogenicity, rFLG2 microneedles could offer a targeted topical therapy addressing mitochondrial dysfunction in dermal papilla cells; dose-finding and early human trials are warranted.